Teleflex Q3 revenue slightly beats estimates
TFX•Teleflex's third-quarter revenue rose 0.2% year over year to $567.78 million, slightly above estimates, while adjusted diluted EPS of $2.63 beat the $1.90 consensus. The company raised its 2026 adjusted diluted EPS guidance to $7.50-$7.75 and maintained its revenue growth outlook of 3.5%-4.5%.
1. Quarterly results
Teleflex reported third-quarter revenue of $567.78 million, up 0.2% year over year and slightly above the $566.77 million analyst consensus. Adjusted diluted EPS was $2.63, compared with the $1.90 consensus; diluted EPS from continuing operations was $1.30.
2. 2026 guidance
The company maintained its 2026 pro forma adjusted constant currency revenue growth guidance at 3.5%-4.5% and raised its adjusted diluted EPS guidance from continuing operations to $7.50-$7.75. It lowered its GAAP revenue growth guidance to 13.2%-14.2%, citing foreign exchange changes.
3. Business drivers
Teleflex said its Vascular and Surgical units delivered mid-single-digit growth, while Interventional returned to modest growth. Third-quarter results included $16.5 million in IEEPA tariff refunds recognized in continuing operations; the company also cited margin expansion as contributing to EPS growth excluding those refunds. It repurchased $350 million in stock since July 1, 2026.
